Compare Spotify Technology (SPOT) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spotify Technology vs Twist Bioscience Corp — how do they compare? Spotify Technology trades at $524 (market cap $108.68B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Spotify Technology is far larger — about 12.9× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Spotify Technology nearer its low. Which is the better fit depends on your goals.
| SPOT | TWST | |
|---|---|---|
Market Cap | $108.68B | $8.42B |
Sector | Media | Health |
52-Week High | $738.53 | $153.10 |
52-Week Low | $412.75 | $24.16 |
Enterprise Value | $98.31B | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Spotify (SPOT) trades at $528.64, down 2.54% on the day, but maintains a bullish technical outlook with strong fundamental momentum. The company reported record profitability with net income reaching $2.21 billion in 2025, representing a 12.87% margin, while revenue grew to $17.19 billion. Recent news highlights a $1.5 billion share repurchase authorization and ongoing subscriber growth, though Q2 2026 earnings missed expectations.
The stock presents a compelling growth story with expanding margins and positive cash flow generation, but faces valuation risks with a P/E of 28.61. Analyst consensus remains bullish with a $590.29 price target, representing 11.7% upside potential. Key risks include execution pressure to justify premium valuation and competitive threats in the audio streaming space.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
